ClinicalTrials.gg
CompletedNCT03146988Updated Nov 22, 2017

Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta

A Phase 1 interventional study of RGB-02 or Neulasta® (pegfilgrastim) in Bioequivalence, sponsored by Gedeon Richter Plc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-22.

Sponsored by Gedeon Richter Plc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Single-centre, double-blind, randomised, two-period, two-way crossover study to investigate the pharmacokinetics and pharmacodynamics of RGB-02 as compared to Neulasta® administered as a single subcutaneous injection in healthy adult subjects.

02

Conditions studied

  • Bioequivalence
03

In context

Lead sponsor

Gedeon Richter Plc. is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or non-pregnant, non-lactating healthy females aged 18 to 55 years
  • ≥19.0 to ≤30.0 kg/m2
  • Body weight >55 kg"

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to filgrastim, pegfilgrastim or lenograstim (Period 1 only)
  • Subjects who have received any IMP in a clinical research study within the previous 3 months
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
  • Current smokers who smoke more than 10 cigarettes per day
  • Positive drugs of abuse test result
  • Serious adverse reaction or serious to any drug or the formulation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    RGB-02 6 mg SC (test product)

    Drug: RGB-02 or Neulasta® (pegfilgrastim)

  • Active comparator
    Neulasta®

    Drug: RGB-02 or Neulasta® (pegfilgrastim)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter: AUC0-inf

    Area under the serum concentration vs time curve from dosing to the last measured time point

    Time frame: 67 days

  2. Pharmacokinetic parameter: Cmax

    Time frame: 67 days

  3. Pharmacodynamic parameter: ANCmax

    Time frame: 67 days

  4. Pharmacodynamic parameter: ANC AOBEC0-tlast

    Time frame: 67 days

07

Study locations

1 site
  • Quotient Clinical
    Ruddington, Nottingham NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Sep 2017, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2017
First posted
May 10, 2017
StartActual
Apr 10, 2017
Primary completionActual
Sep 14, 2017
CompletionActual
Oct 4, 2017
Last update
Nov 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03146988
Lead sponsor
Gedeon Richter Plc.
Responsible party
Sponsor
First posted
May 10, 2017
Start date
Apr 10, 2017
Primary completion
Sep 14, 2017
Completion
Oct 4, 2017
Last update
Nov 22, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion